horary plasmatic dosages of dopa and metabolites in 30 treated parkinsonian patients have shown that , within the group of patients treated with l-dopa combined with an extracerebral decarboxylase inhibitor , highly significant by increased plasmatic o-methyl-dopa levels can be found in patients with dyskinesias compared with those without dyskinesias .
C0023570
l-dopa
C0013023
dopa